tbuckley/cabot-search huggingface dataset:
Extracellular Tyrosyl-tRNA Synthetase Is a Potent Stimulator of Thrombocytopoiesis
Authors: Sachiko Kanaji, Taisuke Kanaji, My-Nuong Vo, Alessandro Zarpellon, Ryan Shapiro, Rajesh Belani, Minh-Ha Do, Xiang-Lei Yang, Zaverio M. Ruggeri, Paul Schimmel
Journal: Blood (2016)
A&amp;E performing better than last year but missed targets an ongoing concern, say medical leaders
Authors: Gareth Iacobucci
Journal: BMJ (2019)

Clinical leaders have urged the NHS to renew its commitment to meeting key performance targets after figures showed that the service remained in breach in most areas.

Latest NHS England performance statistics1 show slightly improved emergency department performance compared with last winter, with 86.4% of patients seen in four hours in December 2018 compared with 85% in December 2017. The NHS also saw 3.9% more people within the four hour target in December 2018 compared with last year. This followed extra preparation ahead of winter, coupled with mild weather and low flu rates in December.

But the service continues to be in breach of most key targets. In December 2018, only five major …
AB0085 The mechanism of total glucoside of paeony and sinomenine on the prevention of acute gout flares
Authors: Z. Li, X. Ma, D. Li, Z. Lu
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The compliance of drug prevention for acute gout flares (GFs) during urate-lowering treatment (ULT) is very low. New preventive drugs of GFs during ULT is required. Our previous study found that the total glucoside of paeony (TGP), a traditional Chinese drug's extracts, has a good effect on the prevention and treatment for urate induced acute gouty arthritis (AGA) in rat. <h3>Objectives</h3> To explore the possible mechanism of TGP and Sinomenine (SIN) in the prevention and treatment of acute gouty arthritis. <h3>Methods</h3> Logarithmic growth phase of RAW264.7 cells were seeded into 96 well plate at a density of 5 × 10<sup>4</sup>/mLl. Cultured overnight in a humidified atmosphere of 5% CO<sub>2</sub> at 37°C. Then, the medium was changed to serum-free DMEM. Then divided into Control group (DMEM), Model group (DMEM +50 mg/L MSU), Colchicine group (DMEM +50 mg/L MSU +1 umol/L Colchicine), TGP group (DMEM +50 mg/L MSU +40 mg/L TGP), SIN group (DMEM +300 mmol/L SIN) , SIN +TGP group (DMEM +40 mg/L TGP +300 mmol/L SIN) . The final volume of solution was 2 ml in each well, and each group had 3 wells, culturing for 24 hour in a humidified atmosphere of 5% CO<sub>2</sub> at 37°C. Then, culture supernatant was collected. NO level were detected by method of nitrate reductase, the level of IL-1β, TNF-α, IL-8, MCP-1, MIF were detected by ELISA method. Western blot method was used to detect the expression of MyD88, NF-κB, ASC, and Caspase-1 in macrophages. <h3>Results</h3> The expression level of MyD88, NF-κB, ASC and Caspase-1 protein in macrophages of model group was significantly up-regulated, and the levels of IL-1β, TNF-α, IL-8, MCP-1, MIF and NO in the supernatant is increased significantly. TGP, SIN, TGP +SIN and Colchicine group compared with the model group, the expression of NF-κB, MyD88, ASC, Caspase-1 protein in macrophage and the level of IL-1β, TNF-α, IL-8, MCP-1, MIF and NO in supernatant were significantly decreased, the difference was statistically significant (p&lt;0.05). TGP +SIN group compared with Colchicine group, the expression of inflammatory pathways proteins and the levels of inflammatory cytokines were no differenced (p&gt;0.05) (table 1). <h3>Conclusions</h3> The anti-inflammatory effect of Chinese herbal extracts (TGP and SIN) on the multiple targets of the inflammatory model may be one of its mechanisms of action for the prevention and control of acute gout flares. <h3>Reference</h3> [1] Li Zhenbin, Ma Xu, Yang Jing, et al. Effect of total glucosides of peony therapy on acute gouty arthritis and serum levels of IL-1β, IL-6 and TNF-α in rat models. Journal of New Medicine2017;48(6):380–384. <h3>Disclosure of Interest</h3> None declared
AB0669 Maintenance treatment with adalimumab in refractory uveitis due to behÇet’s disease: optimised vs non-optimised group
Authors: J.L. Martín-Varillas, V. Calvo-Río, E. Beltrán, J. Sánchez, M. Mesquida, A. Adán, M.V. Hernández, M. Hernández, E. Valls, L. Martínez, A. Sellas, M. Cordero, M. Díaz, R. Gallego, D. Salom, N. Ortego, J.L. García, J.L. Callejas, J.M. Herreras, A.M. García, O. Maíz, A. Blanco, I. Torre, D. Díaz, E. Pato, E. Aurrecoechea, M.A. Caracuel, F. Gamero, E. Minguez, C. Carrasco, A. Olive, J. Vázquez, O. Ruiz, J. Manero, S. Muñoz, M. Gandía, E. Rubio, F.J. Toyos, F.J. López, J.M. Nolla, M. Revenga, C. González-Vela, J. Loricera, B. Atienza-Mateo, R. Demetrio-Pablo, J.L. Hernández, M.A. González-Gay, R. Blanco
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Uveitis is the most common ocular manifestation in Behçet's Disease (BD), which can cause irreversible blindness.<sup><b>1–2</b></sup> <h3>Objectives</h3> To assess efficacy, safety and cost-effectiveness of adalimumab (ADA) therapy optimisation in a series of patients with uveitis due to BD. <h3>Methods</h3> Multicenter study of 74 ADA-treated patients with BD uveitis refractory to conventional immunosuppressants. Following remission, optimisation was performed by increasing the ADA dosing interval. Comparison between optimised and non-optimised group was performed. <h3>Results</h3> Ocular remission was achieved in 65 (86.6%) patients after a median ADA duration of 6<sup>3–12</sup> months. ADA was optimised in 23 cases. In the remaining 42 ADA was maintained at 40 mg/sc/2 weeks. No baseline differences were found at ADA onset between the optimised and non-optimised groups. Ocular outcomes were similar after a mean ±S.D. follow-up of 34.7±13.3 and 26±21.3 months in the both groups (table 1). Adverse effects were seen in non-optimised group (lymphoma, pneumonia, local reaction and bacteremia). Mean ADA treatment costs were lower in the optimised vs non-optimised group (6101.25 €/patient/year vs 12339.48). <h3>Conclusions</h3> ADA optimisation in BD uveitis refractory to conventional therapy is effective, safe and cost-effective. <h3>References</h3> [1] Calvo-Río V, Blanco R, Beltrán E, et al. Anti-TNF-alfa therapy in patients with refractory uveitis due to Behçet's disease: a 1-year- follow-up study of 124 patients. Rheumatol. 2014; 53(12):2223–31 [2] Santos-Gómez M, Calvo-Río V, Blanco R, et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study. Clin Exp Rheumatol. 2016; 34 (6Suppl 102):S34-S40 <h3>Disclosure of Interest</h3> None declared
SP0129 Studying t cell function in ra and psa
Authors: L. Taams
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> Rheumatoid arthritis (RA) and spondyloarthritis (SpA) describe a group of inflammatory joint diseases affecting ~2% of the population. RA has strong genetic associations with <i>HLA-DR</i>, indicating a role for CD4 +T cells. CD4 +T cells are prominently present in the RA joint, where they can contribute to the inflammatory milieu. I will present recent data from our lab regarding the presence, regulation and function of different CD4 +T cell subsets that are present in the RA joint. In contrast, SpA has strong genetic associations with <i>HLA-B/RUNX3</i> which imply a role for CD8 +T cells. Furthermore, genetic associations with <i>IL23R/TRAF3IP2</i> and the clinical efficacy of IL-17 blockade in SpA, indicate a role for IL-17 in SpA. This provides a strong rationale to investigate the presence, phenotype and functional capacity of IL-17 +CD8+T cells in the joints of patients with SpA. I will present novel data regarding the presence, phenotype and potential function of IL-17 +CD8+T cells in the joints of patients with SpA. Collectively, our data indicate that IL-17 +CD8+T cells may be important contributors to the pathogenesis of SpA. <h3>Disclosure of Interest</h3> L. Taams Grant/research support from: GSK, UCB, Novo Nordisk A/S, Novartis
Metals and Mechanisms of Carcinogenesis
Authors: Qiao Yi Chen, Thomas DesMarais, Max Costa
Journal: The Annual Review of Pharmacology and Toxicology (2019)

Metal exposure is pervasive and not limited to sporadic poisoning events or toxic waste sites. Hundreds of millions of people around the globe are affected by chronic metal exposure, which is associated with serious health concerns, including cancer, as demonstrated in a variety of studies at the molecular, systemic, and epidemiologic levels. Metal-induced toxicity and carcinogenicity are sophisticated and complex in nature. This review provides a broad context and holistic view of currently available studies on the mechanisms of metal-induced carcinogenesis. Specifically, we focus on the five most prevalent carcinogenic metals, arsenic, nickel, cadmium, chromium, and beryllium, and their potential to drive carcinogenesis in humans. A comprehensive understanding of the mechanisms behind the development of metal-induced cancer can provide valuable insights for therapeutic intervention involving molecular targets in metal-induced carcinogenesis.
SAT0175 Response to biologic treatment improves sexual health assessed by the qualisex score in ra
Authors: A. Perdriger, C. Lucas, J. Sibilia, J.-E. Gottenberg
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> Sexual health of RA patients is an aspect of the care often neglected and about which little is known. Qualisex is a simple (10 questions) and valid tool investigating impact of RA on sexuality. This tool can be useful to assess this important aspect of quality of life. (Gossec and al, Clin Exp Rheum,2012). <h3>Objectives:</h3> Qualisex questionnaire was used in active RA patients of the ROC (Rotation or change) study (Gottenberg et al, JAMA 2016) in order to investigate the association between disease activity and response to a biologic treatment and sexual health. <h3>Methods:</h3> Among 153 patients of the randomized controlled trial "ROC", which compared a second anti-TNF to a non-TNF biologic in RA patients with inadequate response to a first anti-TNF. Qualisex questionnaire was proposed to 83 RA patients, and 57 of them filled the questionnaire before and after 6 months of their allocated biologic. Changes in the qualisex score was analyzed according to the variation of the clinical and biological parameters. <h3>Results:</h3> The mean age of the 57 RA patients studied was 50.2 (9.6) years. The mean duration of disease was 11.2 (9.5) years, and 43 (75.4%) were female. After 6 months of treatments, 19 were considered with a good response to the treatment according to EULAR response (DAS 28 VS &lt;3.2 and a variation of 0.6 of the DAS from the base line). The mean value of qualisex score was 4.05 (+/_ 2.53) at V0 and 3.91 (+/_ 2.45) after 6 months of treatment. The variation of the qualisex score was more important among the 19 responder patients than among the 43 patients with a persistently active disease. Changes in the qualisex score was significantly correlated to the changes in DAS28, in asthenia, and in SF36mental score, but not with changes in pain, or in SF36 physical score. Variables correlation with qualisex score P value Variation of DAS 28 CRP 0.33 0.01 Variation of DAS 28 VS 0.27 0.04 Variations of asthenia 0.31 0.03 Variation of pain 0.13 NS Variations of SF 36 physical score -0.21 NS Variation of SF36 mental score -0.3 0.03 <h3>Conclusions:</h3> This first study of sexual health of RA patients in a randomized trial demonstrates an improvement in sexual health in patients responders to a biologic treatment. Improvement of sexual health was associated with a decrease in disease activity and asthenia. <h3>References</h3> 1Gossec L, et al. Elaboration and validation of a questionnaire (Qualisex) to assess the impact of rheumatoid arthritis on sexuality with patient involvement. Clin Exp Rheum2012; 30:0505–13. 2Gottenberg, et al. Non TNF targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient responset o a first anti-TNF. Jama2016;11:1172–1180. <h3>Disclosure of Interest:</h3> None declared
Epigenetic Silencing Affects<scp>l</scp>-Asparaginase Sensitivity and Predicts Outcome in T-ALL
Authors: Aurore Touzart, Etienne Lengliné, Mehdi Latiri, Mohamed Belhocine, Charlotte Smith, Xavier Thomas, Salvatore Spicuglia, Denis Puthier, Françoise Pflumio, Thibaut Leguay, Carlos Graux, Yves Chalandon, Françoise Huguet, Stéphane Leprêtre, Norbert Ifrah, Hervé Dombret, Elizabeth Macintyre, Mathilde Hunault, Nicolas Boissel, Vahid Asnafi
Journal: Clinical Cancer Research (2019)

Biological explanation for discrepancies in patient-related response to chemotherapy depending on the underlying oncogenic events is a promising research area. TLX1- or TLX3-deregulated T-cell acute lymphoblastic leukemias (T-ALL; TLX1/3+) share an immature cortical phenotype and similar transcriptional signatures. However, their prognostic impacts differ, and inconsistent clinical outcome has been reported for TLX3. We therefore hypothesized that the overlapping transcriptional profiles of TLX1+ and TLX3+ T-ALLs would allow identification of candidate genes, which might determine their distinct clinical outcomes.We compared TLX1+ and TLX3+ adult T-ALL outcome in the successive French national LALA-94 and GRAALL-2003/2005 multicentric trials and analyzed transcriptomic data to identify differentially expressed genes. Epigenetic regulation of asparagine synthetase (ASNS) and in vitro l-asparaginase sensitivity were evaluated for T-ALL cell lines and primary samples.We show that TLX1+ patients expressed low levels of ASNS when compared with TLX3+ and TLX-negative patients, due to epigenetic silencing of ASNS by both DNA methylation and a decrease of active histone marks. Promoter methylation of the ASNS gene correlated with l-asparaginase sensitivity in both T-ALL cell lines and patient-derived xenografts. Finally, ASNS promoter methylation was an independent prognostic factor for both event-free survival [HR, 0.42; 95% confidence interval (CI), 0.24-0.71; P = 0.001] and overall survival (HR, 0.40; 95% CI, 0.23-0.70; P = 0.02) in 160 GRAALL-2003/2005 T-ALL patients and also in an independent series of 47 LL03-treated T lymphoblastic lymphomas (P = 0.012).We conclude that ASNS methylation status at diagnosis may allow individual adaptation of l-asparaginase dose.
Phase II Trial of CH5424802 (alectinib hydrochloride) for Recurrent or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Authors: Masahiro Sekimizu, Reiji Fukano, Ilseung Choi, Akiko Kada, Akiko Saito, Ryuta Asada, Tetsuya Mori, Hirokazu Nagai
Journal: Blood (2018)
Synergistic Pre-Clinical Activity of Targeted Inhibition of KDM1A and BET Proteins Against Human AML Blast Progenitor Cells
Authors: Warren Fiskus, Christopher Peter Mill, Raffaella Soldi, Roulan Han, Dyana T. Saenz, Agnieszka J Nowak, Baohua Sun, David N Saenz, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Wendy Jin, Thurika Ganesh, Vaishnavi Rao, Joseph David Khoury, Sunil Sharma, Kapil N. Bhalla
Journal: Blood (2018)
FRI0525 Association between dietary vitamin k intake with knee symptoms and back pain in patients with knee osteoarthritis
Authors: Z. Liao, J. Chang, Z. Zhu, W. Han, T. Meng, S. Zheng, T. Winzenberg, A. Wluka, F. Cicuttini, C. Ding
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Vitamin K could be implicated in structural change of osteoarthritis (OA), but current evidence is limited or conflicting so the association between vitamin K and OA symptoms remains unclear. <h3>Objectives</h3> This study aims to investigate the association of vitamin K intake with knee symptoms and structural features in people with knee OA. <h3>Methods</h3> The parent study, Vitamin D Effect on Osteoarthritis (VIDEO) study, was conducted between June 2010 and December 2013 in Tasmania and Victoria, Australia. Knee symptoms were assessed using the Western Ontario and McMaster University Index of osteoarthritis (WOMAC) and a Visual Analogue Scale (VAS) for pain. A validated Food Frequency Questionnaire (FFQ) (developed by the Cancer Council Victoria in Australia) was completed at baseline and used to determine dietary vitamin K intake. Knee Magnetic Resonance Imaging (MRI) scans were obtained according to a standardised protocol using a 1.5 T whole-body MRI unit. Cartilage volume, cartilage defects, bone marrow lesions and effusion volume were measured. The associations between vitamin K intake quartile and changes in clinical or MRI features were analysed using linear regressions. <h3>Results</h3> 261 participants were included at baseline and 213 completed 2 years of follow-up. There were no significant differences between two equal divisions with high or low level of vitamin K intake in term of baseline characteristics. As table 1 and figure 1 show, higher vitamin K intake quartiles were significantly associated with greater decrease in total WOMAC score and WOMAC function score over 24 months. Similar trends were seen in WOMAC pain score and stiffness score, though not statistically significant. There were no significant associations between baseline vitamin K intake and changes in total cartilage volume, cartilage defects, bone marrow lesions and effusion volume over 24 months. Figure 1 Change in WOMAC score over 24 months among those with different vitamin K intake quartiles <h3>Conclusions</h3> Higher baseline vitamin K intake was associated with decreased knee symptoms over 24 months in patients with knee OA. These suggest that vitamin K intake may be beneficial for knee OA. <h3>Disclosure of Interest</h3> None declared
Significant Differences in Test Availability and Access to Novel Drugs for Multiple Myeloma between Public and Private Hospitals in Latin America. Grupo De Estudio Latinoamericano De Mieloma Multiple (GELAMM)
Authors: Eloisa Riva, Natalia Paola Schutz, Camila Peña, Fiorella Villano, Guillermo J. Ruiz-Argüelles, Juan Ramon Navarro, Willem Bujan, Lidiane Andino Neves, Christine Rojas, Hernán López-Vidal, Angelina Rodriguez, Virginia Bove, Miguel Rodriguez, Dorotea Beatriz Fantl
Journal: Blood (2018)
Semantic integration of clinical laboratory tests from electronic health records for deep phenotyping and biomarker discovery
Authors: Xingmin Aaron Zhang, Amy Yates, Nicole Vasilevsky, J. P. Gourdine, Tiffany J. Callahan, Leigh C. Carmody, Daniel Danis, Marcin P. Joachimiak, Vida Ravanmehr, Emily R. Pfaff, James Champion, Kimberly Robasky, Hao Xu, Karamarie Fecho, Nephi A. Walton, Richard L. Zhu, Justin Ramsdill, Christopher J. Mungall, Sebastian Köhler, Melissa A. Haendel, Clement J. McDonald, Daniel J. Vreeman, David B. Peden, Tellen D. Bennett, James A. Feinstein, Blake Martin, Adrianne L. Stefanski, Lawrence E. Hunter, Christopher G. Chute, Peter N. Robinson
Journal: npj Digital Medicine (2019)

Electronic Health Record (EHR) systems typically define laboratory test results using the Laboratory Observation Identifier Names and Codes (LOINC) and can transmit them using Fast Healthcare Interoperability Resource (FHIR) standards. LOINC has not yet been semantically integrated with computational resources for phenotype analysis. Here, we provide a method for mapping LOINC-encoded laboratory test results transmitted in FHIR standards to Human Phenotype Ontology (HPO) terms. We annotated the medical implications of 2923 commonly used laboratory tests with HPO terms. Using these annotations, our software assesses laboratory test results and converts each result into an HPO term. We validated our approach with EHR data from 15,681 patients with respiratory complaints and identified known biomarkers for asthma. Finally, we provide a freely available SMART on FHIR application that can be used within EHR systems. Our approach allows readily available laboratory tests in EHR to be reused for deep phenotyping and exploits the hierarchical structure of HPO to integrate distinct tests that have comparable medical interpretations for association studies.
SAT0492 Prevalence of the metabolic syndrome in patients with systemic sclerosis
Authors: G. Cuomo, F. Danzo, F. Masini, R. Ferrara, E. Pinotti, C. Romano, L.E. Adinolfi
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The metabolic syndrome is an independent risk factor for ischaemic heart disease. Patients with systemic lupus eriythematosus have un increased prevalence of the metabolic syndrome.<sup>1</sup> There are no controlled studies of the metabolic syndrome in patients with SSc. <h3>Objectives</h3> To compare the prevalence of the metabolic syndrome in patients with SSc and controls and to evaluate its relationship to activity and severity of disease. <h3>Methods</h3> Methods: 50 consecutive patients with SSc (45 female, median age 48; range 20–72) and 50 controls (patients whit fibromyalgia) (45 female, median age 46; range 25–72) were studied. The prevalence of the metabolic syndrome was compared in patients and controls using the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII): central obesity: waist. 102 cm in men and. 88 cm in women;<sup>2</sup> hypertriglyceridaemia:&gt;150 mg/dl;<sup>3</sup> low HDL, 40 mg/dl in men and, 50 mg/dl in women;<sup>4</sup> high blood pressure:&gt;130/85 mm Hg or use of drugs for high blood pressure; and<sup>5</sup> high fasting glucose &gt;110 mg/dl, and associations with activity and severity of the disease were examined. <h3>Results</h3> The metabolic syndrome was present in 24% of patients and in 30% of controls subjects (p&gt;0.05). Among patients with SSc, the metabolic syndrome was significantly associated with higher value of ESR (ESR &gt;30) (5/7 vs 4/34;p=0.027). Neither disease activity nor severity scores were associated with the metabolic syndrome <h3>Conclusions</h3> Patients with SSc have a lower prevalence of the NCEP-ATPIII-defined metabolic syndrome than controls. This result may help to justify the coronary prevalence in SSc patients similar to that of the general population.<sup>2–3</sup> <h3>References</h3> [1] Bengtsson AA, et al. PLoS One2016Jul;21;11(7). [2] Hattema ME, et al. Rheumatology2008;45:578–83. [3] Akram MR, et al. Rheumatology2006;45:1395–8. <h3>Disclosure of Interest</h3> None declared
A Genome-Wide Association Study of > 250,000 Subjects Identifies Novel Risk Loci for COPD
Authors: D. Prokopenko, B. D. Hobbs, P. Sakornsakolpat, N. Reeve, B. Yu, H. Xu, J. Latourelle, J. Nguyen, N. Terzikhan, L. Lahousse, M. Arfan Ikram, K. H. Kim, J. Park, J. Yim, D. Kim, P. Sliwinski, W. Timens, P. D. Pare, Y. Bosse, D. A. Meyers, E. R. Bleecker, Y. Tesfaigzi, S. Belinsky, B. Han, W. Kim, D. P. Strachan, G. G. Bruselle, D. Sparrow, D. L. DeMeo, P. Bakke, A. Gulsvik, J. M. Vonk, A. Manichaikul, S. S. Rich, R. Barr, N. Locantore, R. Tal-Singer, G. T. O'Connor, J. Dupuis, S. London, J. D. Crapo, E. K. Silverman, D. Lomas, I. P. Hall, M. D. Tobin, L. V. Wain, M. Boezen, M. H. Cho
Journal: American Journal of Respiratory and Critical Care Medicine (2018)
Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study
Authors: Niels Abildgaard, Marie-Christiane Vekemans, Barbara Gamberi, Francesco Di Raimondo, Angel Ramirez Payer, Charalampia Kyriakou, Alain Kentos, Elisabeth Kueenburg, Antonia Di Micco, Barbara Rosettani, Pamela Bacon, Margaret Atiba-Davies, Torben Plesner
Journal: Blood (2018)
Superiority of Allogenic Stem Cell Transplantation after Anti-PD1 Therapy over Anti-PD1 Monotherapy Alone in Relapse/Refractory Hodgkin Lymphoma: Real World Evidence from the French Early Access Program
Authors: Guillaume Manson, Jean-Baptiste Mear, Charles Herbaux, Jean Marc Schiano de Collela, Rene-Olivier Casasnovas, Aspasia Stamatoullas, Bénédicte Deau-Fisher, Anna Schmitt, Georges Garnier, Lysiane Molina, Krimo Bouabdallah, Marie-Pierre Moles, Herv Ghesquieres, Adrian Tempescul, Remy Dulery, Emmanuelle Nicolas-Virelizier, Alain Jacques Delmer, Cecile Borel, Adrien Chauchet, Laurent Dercle, Pauline Brice, Roch Houot
Journal: Blood (2018)